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ABSTRACT
Introduction: Approximately 70% of patients with
stroke experience impaired arm function, which is
persistent and disabling for an estimated 40%. Loss
of function reduces independence in daily activities
and impacts on quality of life. Muscles in those who
do not recover functional movement in the stroke
affected arm are at risk of atrophy and contractures,
which can be established as early as 6 weeks
following stroke. Pain is also common. This study
aims to evaluate the feasibility of a randomised
controlled trial to test the efficacy and cost-
effectiveness of delivering early intensive electrical
stimulation (ES) to prevent post-stroke complications
in the paretic upper limb.
Methods and analysis: This is a feasibility
randomised controlled trial (n=40) with embedded
qualitative studies (patient/carer interviews and
therapist focus groups) and feasibility economic
evaluation. Patients will be recruited from the Stroke
Unit at the Nottingham University Hospitals National
Health Service (NHS) Trust within 72 h after stroke.
Participants will be randomised to receive usual care or
usual care and early ES to the wrist flexors and
extensors for 30 min twice a day, 5 days a week for
3 months. The initial treatment(s) will be delivered by
an occupational therapist or physiotherapist who will
then train the patient and/or their nominated carer to
self-manage subsequent treatments.
Ethics and dissemination: This study has been
granted ethical approval by the National Research
Ethics Service, East Midlands Nottingham1 Research
Ethics Committee (ref: 15/EM/0006). To our
knowledge, this is the first study of its kind of the
early application (within 72 h post-stroke) of ES to
both the wrist extensors and wrist flexors of stroke
survivors with upper limb impairment. The results will
inform the design of a definitive randomised controlled
trial. Dissemination will include 2 peer-reviewed
journal publications and presentations at national
conferences.
Trial registration number: ISRCTN1648908;
Pre-results. Clinicaltrials.gov ID: NCT02324634.
INTRODUCTION
Every year in England approximately 110 000
people have a stroke, making it the largest
cause of adult disability.1 Hemiparesis is the
single most disabling factor after stroke, affect-
ing around 80% of patients.2 Approximately
70% of patients with stroke experience
impaired arm function, which is persistent and
disabling for an estimated 40%.2 Loss of func-
tion reduces independence in activities of
daily living (ADL)3 and impacts on an indivi-
dual’s quality of life. Stroke survivors who do
Strengths and limitations of this study
▪ This is the first study to target reciprocally the
flexors and extensors, which although should
have therapeutic benefits with no contraindica-
tions noted, has been ignored by previous elec-
trical stimulation research and clinical practice.
▪ Explores the feasibility of recruiting patients and
starting interventional treatment very early after
stroke (within 72 h).
▪ Incorporates mixed methods and a feasibility
economic component.
▪ Includes short-term and long-term follow-up
(3, 6 and 12 months postrandomisation).
▪ The assessor is not blinded in this small-scale
feasibility study, but methods for ensuring
assessor blinding in the subsequent definitive
trial will be explored.
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not recover functional movement in the paretic arm are
more likely to have pain than those who recover arm func-
tion,4 and are at risk of muscle atrophy and contractures,
which can become established as early as 6 weeks following
stroke.5 There is some evidence that 60% of stroke survi-
vors have contractures6 and they are most common in the
upper limb.7
Recent audit data demonstrate that patients with
stroke are unlikely to receive the recommended 45 min8
per day of each therapy required, for a minimum of
5 days per week.3 In the very acute stages of stroke
rehabilitation, to enable discharge emphasis is often
placed on regaining trunk control and mobility at the
expense of upper limb rehabilitation. Average time
spent in upper limb activities ranges from 0.9 to 7.9 min
per therapy session.9
Several upper limb treatments are used in clinical
practice, with varying success. Some treatments such as
constraint-induced movement therapy and mirror box
therapy have evidence of beneﬁt10–12 but success is
conﬁned to patients with some active movement in the
wrist and hand, and many patients do not. There is
evidence to support early initiation of therapeutic
interventions after stroke, and strong evidence that
intensity of treatment is an important factor in
recovery.13–15
Electrical stimulation (ES) therapy has potential value
for those with reduced or no arm movement after
stroke. ES delivers a small, harmless current that depo-
larises a nerve leading to two actions: a contraction of a
muscle via a motor nerve; and a sensory signal to the
brain and spinal cord by stimulation of the associated
sensory nerves. Stimulation of the muscle causes a con-
traction similar to a naturally produced contraction
which could prevent muscle atrophy. The sensory stimu-
lation of the brain and spinal cord can contribute to
neuroplasticity16 and reduction of pain.4 15
Neuromuscular ES is a safe and harmless treatment
for use in patient groups without the contraindications
of uncontrolled epilepsy, pregnancy and those ﬁtted
with cardiac pacemakers. Metallic implants, cancerous
lesions and risk of brittle bones around the stimulation
site or the joint being treated are also contraindications.
National clinical guidelines2 recommend routine use of
ES for treating ‘foot drop’,3 but there is insufﬁcient
evidence to support the routine use in upper limb
rehabilitation.2 Recently, Rosewilliam et al17 recruited 90
patients with no upper limb function 6 weeks after
stroke and concluded that those who received ES of
wrist extensors showed improved wrist extension,
strength and grip. Secondary analysis concluded ES
prevented the development of pain and deterioration in
contractures.4
The ESCAPS study evaluates the feasibility of conduct-
ing a multicentre randomised controlled trial (RCT) of
the efﬁcacy and cost-effectiveness of early, intensive ES to
prevent wrist joint deformities/contractures, weakness
and upper limb pain after stroke. Qualitative components
will explore barriers and facilitators to protocol adher-
ence and clinical practice implementation.
The national clinical guidelines for stroke recommend
that occupational therapists should aim to ‘re-educate’
the arm of patients who have reduced arm movement
following stroke, by providing repetitive task training.
This is inappropriate for many patients with stroke who
do not have upper limb mobility. Treatment with ES
does not require active movement; therefore, it could
beneﬁt patients who have severe to moderate arm func-
tion deﬁcits.
This RCT is the ﬁrst to study ES of ﬂexors and exten-
sors. Reciprocal stimulation of ﬂexors and extensors will
simulate the natural stretching movement and can be
more effective in the prevention of contractures than
stimulation of extensors alone. Flexor stimulation has
been shown to reduce spasticity rather than being a
contraindication.18 19
In order to prevent deconditioning of the forearm
muscles, there is a need to initiate treatment within 72 h
of stroke. Premature discontinuation of therapy may
reduce any therapeutic effect. No extended trials have
been conducted, so it is important to establish compli-
ance and attrition rates.
To ensure that the results from the deﬁnitive trial are
generalisable, cost-effective and implementable, the
research-related ES treatment will be delivered by
National Health Service (NHS) therapists instead of spe-
cialist research therapists. The best strategy for self-
management needs to be identiﬁed, so that treatment
may continue at home after discharge.
This work will help form the basis for a deﬁnitive trial
in health economics from a societal perspective. Loss of
arm and hand function results in reduction of productiv-
ity, having a huge impact on individual patients and
society.
The NHS needs to ﬁnd effective new ways of man-
aging the upper limb after stroke. This research is
important because it addresses the needs of a signiﬁcant
proportion of patients with stroke. The ESCAPS feasibil-
ity study will inform the design of a deﬁnitive multicen-
tre RCT to evaluate the efﬁcacy and cost-effectiveness of
early ES to the wrist ﬂexors and extensors.
METHODS AND ANALYSIS
Study objectives
The primary objective of the study is to evaluate the
feasibility of a RCT that will test the efﬁcacy of delivering
early, intensive ES to prevent poststroke complications
(such as pain and contractures) to the paretic (weak)
upper limb after stroke.
The objectives of this feasibility study therefore are to
determine whether:
1. It is feasible to recruit within 72 h after stroke event,
and to ascertain recruitment rates.
2. Initiating ES therapy within 72 h after stroke event is
appropriate.
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3. The ES regime proposed, that is, to start receiving ES
on an acute stroke unit twice a day, 5 days a week and
to continue with this schedule postdischarge for up
to 3 months in total, is feasible, as measured by com-
pliance, attrition and the qualitative work.
4. Study the interaction between compliance and
response to treatment in order to identify the
optimum compliance.
5. To determine preliminary health economic informa-
tion surrounding the costs and beneﬁts of the
intervention.
We will also determine in this feasibility study what the
most appropriate inclusion/exclusion criteria are; what
the most sensitive and acceptable outcome measures
are; the optimum method for single blinding and any
barriers to compliance to the protocol from both the
therapist and patient perspectives.
Participants
The study is set in Nottingham, England. Participants
will be patients recruited from the Stroke Unit of the
Nottingham University Hospitals NHS Foundation Trust
within 72 h of stroke event.
Inclusion criteria
Inclusion:
▸ Conﬁrmed clinical diagnosis of stroke;
▸ First stroke event to affect their upper limb;
▸ Aged >18 years;
▸ Impaired arm movement and strength caused by
stroke (determined by the National Institute for
Health Stroke Scale20 (NIHSS) arm subscore).
Exclusion criteria
Exclusion:
▸ An existing chronic upper limb condition (eg, peripheral
nerve injury);
▸ Cardiac pacemaker;
▸ Pregnancy;
▸ Epilepsy;
▸ Undiagnosed pain or skin conditions (not related to
the stroke).
Recruitment
For this feasibility study, we aim to recruit 40 participants
over a period of 17 months from one centre (the
Nottingham Stroke Unit at the Nottingham University
Hospitals NHS Trust). The Clinical Research Network
(CRN) stroke research ofﬁcers will be notiﬁed by the
clinical ward staff of newly admitted (within 72 h post-
stroke) patients with stroke who meet the eligibility cri-
teria. The clinical staff will have screened the patient
against the eligibility criteria and those patients that
meet the eligibility criteria will be informed of the study,
and asked if they give voluntary consent. If the partici-
pant lacks capacity to consent for themselves, consent
will be sought from an approved consultee according to
the Mental Capacity Act. A stroke research ofﬁcer will
visit the patient on the ward to explain the study further
and answer any questions.
Study design
The ESCAPS study is a quantitative single-centre feasibil-
ity RCT (n=40) with an embedded qualitative compo-
nent to evaluate patient recruitment within 72 h of
stroke to receive either routine care with ES or routine
care only.
The RCT is designed as a parallel group, two-arm super-
iority trial with 1:1 allocation ratio.
The embedded qualitative component will explore:
A. Practical implementation issues such as acceptability
of ES treatment to patients and adherence to ES
treatment protocol,
B. Potential barriers and facilitators to incorporation of
ES treatment into routine practice, such as training
of therapy staff.
Using:
1. Three focus groups with physiotherapists (n=4) and
occupational therapists (n=4) involved in delivering
and supporting the ES intervention;
2. Semistructured interviews with a purposive subsample
representing a range of ages, gender and stroke
severity of patient participants and their nominated
carers (intervention group (n=10); control group
(n=5)).
Preliminary economic analysis will test the feasibility of
collecting economic data using a patient resource use
questionnaire.
A schematic diagram of the schedule and time com-
mitment for trial participants in each study group is
included as ﬁgure 1.
Randomisation
Following baseline measures, participants will be rando-
mised to ES therapy intervention or usual care control.
All participants eligible for inclusion will be randomised
on a 1:1 basis. Concealed random allocation will be con-
ducted by a statistician using a computer-generated
pseudo-random list with random permuted blocks of
varying sizes. Allocation concealment will be ensured by
the statistician preparing the randomisation codes in
sealed envelopes that will only be opened by the
researcher after the patient has been recruited and has
completed all baseline measurements. Participants will
be stratiﬁed into four groups (n=10):
1. No arm movement (Action Research Arm Test
(ARAT)21 score=0) and cognitive impairment
(Montreal Cognitive Assessment (MoCA)22 <26);
2. No arm movement (ARAT21 score=0) but no cogni-
tive impairment (MoCA22 >26);
3. Some arm movement (ARAT21 score >1) and cogni-
tive impairment (MoCA22 <26);
4. Some arm movement (ARAT21 score >1) but no cog-
nitive impairment (MoCA22 >26).
A minimisation technique will be applied during ran-
domisation with minimisation on: age, sex, side of stroke
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and severity of arm weakness (as measured by the
NIHSS20 arm subscore).
Intervention treatment
Treatment with current controlled ES is delivered using
a two channel constant current stimulation (maximum
output 100 mA, pulse width 450 μs and a frequency
between 40 and 60 Hz as per participant preference)i.
The motor points for stimulation are selected to
produce reciprocal ﬂexion and extension through full
range of movement.23 The initial assessment and treat-
ment session with an NHS band 5 or above physiother-
apist or occupational therapist will involve identiﬁcation
of the motor points for the forearm ﬂexors and exten-
sors, and placement of self-adhesive electrodes over
these motor points. The current intensity will be
increased to produce an alternating contraction of the
ﬂexors and extensors using a ﬂex-hold-extend-hold
pattern, ensuring that a pure movement is produced
with no ulnar or radial deviation. The skin will be
marked with a skin-safe marker pen to show the correct
area to place the electrodes for future treatments and
the ES device will be locked to the selected settings.
A single stimulation and hold cycle will last 20 s and this
will be cyclically repeated for 30 min after which the
device can be removed.
Clinical staff will assist the patient to apply the elec-
trode pads to the premarked motor points and switch
on the device to the prestored treatment setting (this
will take between 2 and 5 min) for subsequent
treatments. The device will provide treatment without
the need for a therapist to be present.
Prior to hospital discharge, the patient and/or nomi-
nated carer will be taught how to self-manage the treat-
ment where possible. Treatment will continue twice a
day, 5 days a week (Monday to Friday), for a total period
of 3 months.
Modiﬁcations will not be made to the intervention.
A participant may discontinue their allocated interven-
tion or withdraw from the study for the following
reasons: withdrawal of consent, or changes to their
health status preventing their continued participation.
Whenever possible, study participants will be retained in
the trial to enable follow-up data collection and prevent
missing data.
Usual care control
Participants randomised to the control group will not
receive ES therapy but will receive all usual care. ‘Usual
care’ will include all the therapy interventions that are
standard practice on the Nottingham Stroke Unit. As
per national clinical guidelines,2 the application of ES to
the upper limb is not standard practice. It is not possible
to provide a placebo device without the possibility of it
being easily identiﬁed as such. One reason is because
movement is seen in the upper limb when the ES device
is activated; furthermore, participants will be recruited
and start treatment while on the hospital ward, so
control and intervention participants may be in close
proximity on the same wards as each other and would
likely notice a difference between the intervention and
placebo devices.
Adherence to treatment
As part of the feasibility study data on adherence to the
intervention treatment will be collected using two
Figure 1 Schematic diagram of
the schedule and time
commitment for trial participants
in each study group (CRN,
Clinical Research Network; ES,
electrical stimulation; NHS,
National Health Service).
iThe NeuroTrac Rehab Verity Medical Limited in compliance with the
European Union Medical Device Directive MDD93/42/EEC under the
supervision of SGS, notiﬁed body number 0120 CE mark status. Verity
Medical Ltd is certiﬁed by SGS to the following quality standards: ISO
9001:2008, ISO13485:2003.
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different methods. The ES devices have an internal
memory function that will record data on usage. In add-
ition, the study participants and/or their nominated
carers will be asked to complete a patient diary to show
the days and times that they have used the device. These
data will be collected during the 3-month outcome
assessment visit.
Concomitant interventions during the trial
Participants enrolled on the ESCAPS trial cannot be
enrolled in any other concomitant trials involving the
application of experimental upper limb interventions
that may impact trial outcomes.
Blinding
It will be difﬁcult to blind this study as the investigator
and patient cannot be blinded during the procedure.
However, an objective of this feasibility is to ascertain the
most appropriate blinding procedure for the ensuing
deﬁnitive trial.
The lead ward therapist will be informed of group
allocation as they (or a nominated qualiﬁed therapist)
will be providing the initial treatment. We will take every
step to minimise allocation and outcome bias. Trial par-
ticipants will not be blinded to group allocated because
they will need to be informed as to whether they have
been allocated to the intervention group receiving the
ES therapy, or the control group who will not receive
any ES therapy intervention.
The researcher responsible for the completion of
outcome measures will not be blinded to group alloca-
tion as data on compliance will need to be collected via
the use of participant diaries that will be collected at the
3-month follow-up assessment. This researcher will also
have to record data on the number of ES treatments
recorded (to measure home compliance) by the ES
devices’ internal memory function (current intensity in
mA and total time the device is used).
Outcome measures
The primary outcomes relate to the feasibility outcomes
of the study.
1. Feasibility of the trial design:
▸ Recruitment rates: number/per cent of partici-
pants recruited within 72 h post-stroke; time
post-stroke that participants received their ﬁrst
treatment;
▸ Recruitment strategy: number/per cent of
patients screened, number/per cent eligible
and approached, number/per cent who con-
sented, number/per cent excluded after
screening;
▸ Completion/attrition rates: number/per cent of
participants who completed the intervention;
▸ Compliance/adherence to treatment protocol:
number/per cent of participants who received
ES twice a day, 5 days a week while in hospital,
and number/per cent who continued with the
treatment regime after discharge. Mean,
minimum and maximum number of ES treat-
ments that participants received during the
3-month intervention period;
▸ Consultee consent rates: number/per cent of
patients unable to give informed consent, and
number/per cent consented by a consultee,
number of consultees who declined consent;
2. Tolerability: number of participants who withdraw or
decline intervention; records of interventions
declined and why;
3. Integrity of the study protocol: measured by examin-
ing how many participants are able to complete the
study, number/per cent of missing data, and
number/per cent of people who completed each of
the outcome measures at 3-month, 6-month and
12-month follow-up, calculation of the cost of
running the study; analysis of the qualitative interview
and focus group data. The secondary outcomes
relate to clinical outcome measures. Demographic
characteristics (age, gender, ethnicity and socio-
economic status), stroke characteristics (date, type
and side of stroke), cognitive status (MoCA22) and
premorbid function state (Nottingham Extended
ADL (NEADL)24) will be collected at baseline.
Participants will complete the following assessments at
0, 3, 6 and 12 months:
▸ Neurological outcome (NIHSS20 score);
▸ Independence in daily activities (Barthel ADL Index
score25 and modiﬁed Rankin Scale (mRS)26 27);
▸ Pain in the affected arm (Scale of Pain Intensity
(SPIN)28);
▸ Muscle contractures/muscle activity (Biometrics EMG
equipment);
▸ Arm function (ARAT21);
▸ Stroke-related quality of life (Stroke Speciﬁc Quality
of Life Scale (SS-QOL))29;
▸ Health status (EuroQol-5D (EQ-5D)30);
▸ Patient resource use questionnaire;
▸ Carer strain (Caregiver Strain Index (CSI)31) will be
completed by the participant’s nominated carer.
Data collection methods
Following recruitment to the trial, a stroke researcher
will visit the participant on the ward to obtain the base-
line measurements. In cases where it is not possible to
obtain all the outcome measurement data from the
patient or the medical records, for the BI, NEADL,
mRS, resource use questionnaire, the researcher will
obtain by proxy data from the next of kin. A stroke
researcher will visit the participant at their place of dis-
charge to complete the 3-month, 6-month and
12-month follow-up assessments.
Sample size
This is a feasibility study and therefore the sample size is
determined by the number of participants that is feas-
ible to study within the timescale of the project.
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Consecutive sampling will be used to recruit 40 partici-
pants. This will provide sufﬁcient information to indicate
feasibility. Outcome data will be utilised to inform a
sample size calculation for the deﬁnitive trial by asses-
sing variability and completeness of data.
Data management
Case report forms (CRFs) and all measurement data
(with the exception of the spasticity and contracture
measurement data) will be completed on paper forms.
Data will then be entered and stored in a password pro-
tected electronic database. The original paper copies of
CRFs and all study data will be treated as conﬁdential
documents and held securely in accordance with regula-
tions. Participants will each be assigned a unique trial
identity code for use on all study documents. All source
documents will be ﬁled at the principal investigator’s site.
Data analysis
Data will be statistically summarised/analysed using
SPSS, and MathCad will be used to extract measures
related to spasticity and contractures. Analyses will cover
the following:
▸ Total patients recruited within 72 h of stroke event;
average length of time post-stroke when patients
received ﬁrst treatment.
▸ Total patients screened, eligible and approached,
consented, and excluded after screening.
▸ Total patients who completed the intervention;
number who completed 3-month, 6-month and
12-month follow-up assessments.
▸ Total participants receiving ES per protocol (PP);
mean, minimum and maximum number of ES treat-
ments received during 3-month intervention period;
qualitative patient/carer interview data, and ES
machine’s memory which records number of sessions
and duration.
▸ Total patients unable to give informed consent;
number consented by consultee; number of consul-
tees who declined.
▸ Recruitment and attrition rates, number of patients
lost to follow-up and reasons.
▸ Quality of health economic data between assessment
points especially 6–12 months regarding complete-
ness. Cross referencing of data against medical
records where possible. Sensitivity of the EQ-5D in
measuring outcome. Combined cost and outcome
analysis to determine potential cost-effectiveness of
ES verses usual care.
▸ Thematic analysis will be used to identify themes rep-
resentative of patient experience of treatment, and
the experience of carers with the application of the
ES device.
As the sample size is small and a method of minimisa-
tion is used, we propose to estimate effect size (using
the Cohen’s d and the 95% CI) for the main study mea-
sures that are interval level data. The OR (and the 95%
CI) will be estimated when data are dichotomous. When
measures are ordinal, nominal relative risk ratios will be
used to present all forms of adverse events.
In addition to estimating effect size, we will explore
the use of the following statistical techniques to analyse
our data: The group of patients randomised to receive
the active treatment will be compared with the control
group for all our primary outcomes variables recorded.
Continuous variables that are normally distributed will
be analysed using generalised linear modelling techni-
ques. Where repeated measures have been recorded, we
will apply generalised estimating equation techniques,
considering appropriate correlation structure, with time
interaction. For continuous variables, treatment differ-
ences will be presented with associated 95% CIs. For all
statistical tests p<0.05 (2-sided) will be considered statis-
tically signiﬁcant.
No additional secondary analyses (eg, subgroup or
adjusted analyses) are planned for this feasibility study.
For this study, the following deﬁnitions of analysis
population will be followed:
All-available-patient population: All patients who have
consented for the study will be used for patient account-
ability and listings and will include patients who are ran-
domised but who do not receive their ES intervention
treatment.
Intention-to-treat (ITT) population: All patients who have
been randomised and received their ES treatment inter-
vention at baseline and who complete follow-up assess-
ment at 3 months, 6 months and 12 months will be
included in an ITT population.
The PP population: All patients included in the ITT
population, who participate in the study, without major
protocol violation.
Missing values will be imputed by using the last value
carried forward. We acknowledge that this method is
associated with a risk of bias in patients who are
deteriorating.
Trial status
The ofﬁcial study start date was 1 April 2015. Recruitment
to the feasibility trial began on the 1 June 2015 with the
ﬁrst patient entered into the study on 5 June 2015.
ETHICS AND DISSEMINATION
Informing potential trial participants of possible benefits
and known risks
The stroke research ofﬁcer will provide the patient and
their consultee (if appropriate) with a verbal explan-
ation of the trial and written patient information sheets,
ensuring that the participant has sufﬁcient time to con-
sider participating or not. The CRN research ofﬁcer will
answer any questions that the participant has concerning
study participation.
Obtaining informed consent from participants
Trained stroke research ofﬁcers will obtain written
informed consent from patients willing to participate in
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the trial. The informed consent form will be signed and
dated by the participant before they enter the trial and
before they undergo any interventions (including
history taking) related to the study. Patients who are
unable to sign their name because the stroke has
affected their dominant hand and they are unable to
sign a legible signature with their non-dominant hand
will be asked to point to a box within the consent form
and a witness will sign to state that the patient wished to
give informed consent to participate in the study.
An ‘aphasia friendly’ version of the information sheets
and consent form will be available for those with com-
munication difﬁculties. Such aphasia friendly informa-
tion sheets and consent forms have been used in
previous stroke trials by the study team.
Patients who lack the mental capacity to consent to par-
ticipate in the study will be recruited after consultation
with their next of kin or nominated carer. Consultee
advice will be obtained from the patient’s relative or close
friend who would know the patient’s wishes. Capacity is a
situation-speciﬁc assessment and the CRN staff and clin-
ical stroke team have had training in assessing capacity.
Those participants who lack capacity will be considered
for recruitment to the main feasibility trial only and not
participation in the patient and carer interviews.
Irrespective of patients’ mental capacity, verbal or ges-
tured agreement will be sought prior to ES treatment,
and objections will be respected. If a participant becomes
distressed by the ES treatment, it will be stopped.
Participants who lack capacity to provide informed
consent will not be recruited to the patient and carer
interview part of the study, but their nominated carer
may opt to be interviewed about their experience of sup-
porting someone without capacity to participate in the
trial.
Owing to the early delivery of ES within 72 h post-
stroke, it may be that obtaining informed consent from
the patient is not possible due to communication and/
or cognitive difﬁculties. In these circumstances, we will
obtain consultee consent. However, if during the inter-
vention period the patient regains their communication
and/or cognitive function, we will obtain informed
consent from the patient at that time.
Study withdrawal
It will be explained to the potential participant or their
consultee that entry into the study is entirely voluntary
and that treatment and care of the participant will not
be affected by their decision. Participants or their con-
sultee will be informed that they can withdraw from the
study at any given point and that this will not affect their
future care. Participants may be withdrawn from the trial
either at their own request or at the discretion of the
investigator. The participants will be made aware that
this will not affect future care. Participants will be made
aware (via the information sheet and consent form) that
should they withdraw, the data collected to date cannot
be erased and may still be used in the ﬁnal analysis.
Participants may discontinue their allocated intervention
or withdraw from the study for the following reasons:
▸ Withdrawal of consent,
▸ Changes to their health status preventing their con-
tinued participation.
Enrolled participants who withdraw and were not yet
randomised will be replaced (though the withdrawn par-
ticipant will keep their trial ID). Participants who with-
draw after randomisation will not be replaced.
Data protection and confidentiality
All trial staff and investigators will endeavour to protect
the rights of the trial’s participants to privacy and
informed consent, and will adhere to the Data
Protection Act 1998. The CRF will only collect the
minimum required information for the purposes of the
trial. CRFs will be held securely in a locked ﬁling
cabinet with access limited to the trial staff. Computer
held data including the trial database will be held
securely on a dedicated web server and will be encrypted
and password protected. Participant conﬁdentiality will
be ensured by utilising identiﬁcation code numbers.
Individual participant medical information obtained as a
result of this study are considered conﬁdential and dis-
closure to third parties is prohibited.
Access to the CRFs shall be restricted to those person-
nel approved by the principal investigator and recorded
on the Trial Delegation Log. The full data set will be
restricted to the Trial Management Group, Independent
Trial Steering Consultant and Sponsor. On completion
of the study and following dissemination of the ﬁndings,
secondary anonymised data will be available on request.
Research governance and the conduct of the trial
The trial is being conducted in accordance with the
ethical principles that have their origin in the
Declaration of Helsinki 1996, the principles of Good
Clinical Practice, and the Department of Health
Research Governance Framework for Health and Social
Care 2005.
Dissemination of research findings
As this is a feasibility study, the main dissemination strat-
egy will be after the ensuing trial. The ﬁndings from this
study will be disseminated through study reports,
through publications in academic peer reviewed jour-
nals, and conference presentations. The results will be
communicated to the participants and involved stroke
unit staff in the form of a letter thanking them for their
involvement and support of the study, along with a lay
summary of the ﬁndings and plans for future research.
Clinical trials authorisation
Clinical trials authorisation is not required.
Trial management and regulatory issues
This study is being hosted by Nottingham University
Hospitals NHS Trust and coordinated by the University
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Table 1 All items from the WHO trial registration data set
Data category Information
Primary registry and trial
identifying number
ISRCTN Registration
ISRCTN16489086
Date of registration in primary
registry
15/01/2015
Secondary identifying numbers ClinicalTrials.gov
NCT02324634
Source(s) of monetary or
material support
Monetary support: Department of Health funding from the NIHR RfPB programme
(PB-PG-1013-32034)
Material support: NeuroTrac Rehab devices used for the intervention were donated by
Verity Medical Ltd
Primary sponsor University of Nottingham
Secondary sponsor(s) Nottingham University Hospitals NHS Trust
Contact for public queries JCF-S (principal investigator)
Joanna.fletcher-smith@nottingham.ac.uk
Contact for scientific queries JCF-S (principal investigator)
Joanna.fletcher-smith@nottingham.ac.uk
Public title Early Electrical Stimulation to prevent Complications to the Arm Post-Stroke—a feasibility
study (ESCAPS)
Scientific title Early electrical stimulation to the wrist extensors and wrist flexors to prevent the post-stroke
complications of pain and contractures in the paretic arm—a feasibility study
Countries of recruitment England, UK
Health condition(s) or problem
(s) studied
Stroke: prevention of post-stroke complications (eg, pain and contractures) in the upper
limb
Intervention(s) ES applied to the wrist extensors and wrist flexors for 30 min, twice a day, 5 days a week,
for 3 months
The ES will be set to deliver a 450 μs pulse at a frequency of 40–60 Hz (as per patient
convenience). The intensity of the current will be increased to produce an alternating
contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single
stimulation and hold cycle will last 20 s and this will be cyclically repeated for 30 min
Control group will receive usual care only and will not receive any ES treatment
Key inclusion and exclusion
criteria
Inclusion criteria:
▸ Confirmed clinical diagnosis of first disabling stroke event affecting the upper limb
▸ Aged >18 years
▸ Impaired arm movement and strength (NIHSS arm subscore >0) resulting in reduced
function, caused specifically by the stroke
Exclusion criteria:
▸ Previous history of stroke affecting their upper limb
▸ Peripheral nerve injury/existing orthopaedic condition affecting the upper limb; fixed
contractures at the elbow, wrist or fingers; malignancy in the area of the ES electrode
placement; or epilepsy
▸ Cardiac pacemaker or similar implanted device
▸ Pregnancy
▸ Undiagnosed pain or skin conditions (not related to the stroke)
Study type Feasibility RCT (single centre)
Interventional
Allocation: randomised
Masking: unblinded (for practical reasons during the feasibility trial but in any subsequent
pilot and definitive trials the outcomes assessor will be blinded)
Date of first enrolment June 2015
Target sample size 40
Recruitment status Recruiting
Primary outcome(s) Pertain to the feasibility aims of the study:
1. Feasibility of the trial design (12 months)—recruitment rates: number/per cent of
participants recruited within 72 h post-stroke; time post-stroke that participants received
their first treatment; recruitment strategy: number/per cent of patients screened, number/
per cent eligible and approached, number/per cent who consented, number/per cent
excluded after screening; completion rates: number/per cent of participants who
completed the intervention; number/per cent of participants who received ES twice
Continued
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of Nottingham (the research sponsor). The principal
investigator ( JCF-S) will manage the day-to-day running
of the study. The Trial Management Group will meet
quarterly throughout the trial to discuss progress, includ-
ing recruitment, withdrawals, treatment compliance,
clinical issues and dissemination plans. As this is a feasi-
bility study, the funder does not require a formal Trial
Steering Committee or Data Monitoring Committee.
However, an independent Trial steering Consultant will
monitor and supervise the progress of the study towards
its interim and overall objectives; concentrate of progress
of the trial, adherence to the protocol and consideration
of new information of relevance to the research ques-
tion; provide advice on all appropriate aspects of the
trial; and agree proposals for substantial protocol
amendments. This independent monitor will audit the
core trial processes and documents
Any potential modiﬁcations to the protocol will be dis-
cussed and agreed by the Trial Management Group,
Trial Steering Consultant and the research Sponsor.
Permission for a formal amendment to the protocol will
then be sought from the Research Ethics Committee
who granted the original ethical approval for the study.
The local NHS Research and Development ofﬁce will
then be notiﬁed of any approved amendments.
Table 1 shows all items from the WHO trial registra-
tion data set.
Adverse events
The occurrence of an adverse event as a result of partici-
pation is not expected and no adverse event data will be
collected. The ES device itself is not under investigation
and these devices have already passed extensive safety
testing and are considered safe for use by patients with a
range of conditions including stroke. Such devices are
currently used in some areas of clinical practice on an
ad hoc basis. The manufacturer’s advice will be followed
with regard to excluding patients who have a contraindi-
cation (eg, implanted cardiac pacemaker, epilepsy, preg-
nancy, malignancy in the area of the electrode
placement).
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Table 1 Continued
Data category Information
a day, 5 days a week while in hospital, and number/per cent who continued with the
treatment regime after discharge. Mean, minimum and maximum number of ES
treatments that participants received during the 3-month intervention period; recruitment
of patients lacking mental capacity to consent for themselves: consultee consent rates
(number/per cent of patients unable to give informed consent, and number consented
by a consultee, number of consultees who declined consent)
2. Tolerability (12 months)—proportion of participants who withdraw or decline intervention;
records of interventions declined and why
3. Integrity of the study protocol (12 months)—measured by examining how many
participants are able to complete the study, per cent of missing data, and per cent of
people who completed each of the outcome measures at 3-month, 6-month and
12-month follow-up, calculation of the cost of running the study
Key secondary outcomes 1. NIHSS score (0, 3, 6, 12 months)—neurological outcome and degree of recovery
2. Barthel ADL Index score and modified Rankin score (0, 3, 6, 12 months)—
independence (functional ability) in basic daily activities
3. SPIN (0, 3, 6, 12 months)—pain in the affected arm
4. Muscle contractures (reduction in range of movement and spasticity; 0, 3, 6,
12 months)—muscle contractures will be monitored by measuring muscle activity
during assessments using Biometrics equipment
5. ARAT (0, 3, 6, 12 months)—arm function
6. SS-QOL (0, 3, 6, 12 months)—stroke-related quality of life
7. EQ-5D (0, 3, 6, 12 months)—health status
8. Patient resource use (cost) questionnaire (0, 3, 6, 12 months)—a measure of resource
use and health-related costs
9. CSI (0, 3, 6, 12 months)—carer strain
10. NEADL (0 months)—premorbid functional state
11. MoCA (0 months)—cognitive status at baseline
ADL, activities of daily living; ARAT, Action Research Arm Test; CSI, Caregiver Strain Index; ES, electrical stimulation; EQ-5D, EuroQoL-5D;
ISRCTN, International Standard Randomised Controlled Trial Number; MoCA, The Montreal Cognitive Assessment; NEADL, Nottingham
Extended ADL; NHS, National Health Service; NIHR, National Institute for Health Research; NIHSS, National Institute for Health Stroke Scale;
RCT, randomised controlled trial; RfPB, Research for Patient Benefit; SPIN, Scale of Pain Intensity; SS-QOL, Stroke Specific Quality of Life
Scale.
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